--- title: "Genflow Biosciences PLC 宣佈其總投票權" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/281138115.md" description: "Genflow Biosciences PLC 宣佈，截至 2026 年 3 月 31 日，其總髮行股本為 535,653,205 股普通股，投票權數量相同。該數字將用於股東確定是否需要根據金融行為監管局的規則通知其投資變動。Genflow 是一家專注於針對與年齡相關疾病的基因療法的生物技術公司，目前正在對其主要化合物 GF-1002 進行臨牀試驗，該化合物針對慢性肝病，旨在改善老年人羣的健康" datetime: "2026-03-31T06:55:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281138115.md) - [en](https://longbridge.com/en/news/281138115.md) - [zh-HK](https://longbridge.com/zh-HK/news/281138115.md) generator: "portal-rs" --- # Genflow Biosciences PLC 宣佈其總投票權 **LONDON, UK / ACCESS Newswire / March 31, 2026 /** Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 31 March 2026 consists of 535,653,205 ordinary shares of £0.0003 each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 535,653,205. The figure of 535,653,205 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. **Contacts** **Genflow Biosciences** **Harbor Access** Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 475 477 9401 Jonathan.Paterson@Harbor-access.com **About Genflow Biosciences** Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. **SOURCE:** Genflow Biosciences PLC View the original press release on ACCESS Newswire ### 相關股票 - [BGLC.US](https://longbridge.com/zh-HK/quote/BGLC.US.md) - [IDNA.US](https://longbridge.com/zh-HK/quote/IDNA.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [GNCAQ.US](https://longbridge.com/zh-HK/quote/GNCAQ.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) ## 相關資訊與研究 - [SBIO：美國程序化廣告和 EMEA 地區貢獻了第二季度 49% 的銷售額，利潤率上升至 61%，預計將在 2026 年下半年實現盈利](https://longbridge.com/zh-HK/news/296517769.md) - [國泰資產管理公司認為，流動性的增加將推動中國生物技術和創新藥品股票的上漲](https://longbridge.com/zh-HK/news/296448906.md) - [EverGen 基礎設施公司公佈 2026 年第二季度財報 | EVGIF 股票新聞](https://longbridge.com/zh-HK/news/297122882.md) - [生物科技股將在 2026 年 9 月面臨 FDA 的決策](https://longbridge.com/zh-HK/news/297065559.md) - [Su-Leng Tan Lee 披露在 BioNexus Gene Lab Corp 的投資，持有 11.5% 的股份](https://longbridge.com/zh-HK/news/295980100.md) --- > **免責聲明: 本文僅供參考，不構成任何投資建議。**